ARGX vs QGEN
Argenx SE and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ARGX | QGEN |
|---|---|---|
| Revenue | $4.2B | $2.1B |
| Net income | $1.3B | $424.9M |
| Gross margin | 89.1% | 62.2% |
| Net margin | 31.1% | 20.3% |
| Return on equity | 20.2% | 11.6% |
| Diluted EPS | $19.57 | $1.94 |
| Dividend / share | · | $0.25 |
| Payout ratio | · | 12.8% |
| Free cash flow | $679.0M | $453.3M |
| Equity | · | $3.8B |
| Net debt / equity | · | 0.22× |
| Current ratio | 5.23× | 3.90× |
| Revenue CAGR 5y | 151.5% | 2.2% |
| Profit CAGR 5y | · | 3.4% |
ARGX bills 2.0× the revenue of QGEN, and keeps more of each dollar of revenue as profit (31.1% against 20.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ARGX | QGEN |
|---|---|---|
| FY2025 | $4.2B | $2.1B |
| FY2024 | $2.2B | $2.0B |
| FY2023 | $1.2B | $2.0B |
| FY2022 | $400.7M | $2.1B |
| FY2021 | $497.3M | $2.3B |
| FY2020 | $41.2M | $1.9B |
| FY2019 | $78.5M | $1.5B |
| FY2018 | · | $1.5B |
| FY2017 | · | $1.4B |
| FY2016 | · | $1.3B |
Bottom line
| Fiscal year | ARGX | QGEN |
|---|---|---|
| FY2025 | $1.3B | $424.9M |
| FY2024 | $833.0M | $83.6M |
| FY2023 | $-295.1M | $341.3M |
| FY2022 | $-709.6M | $423.2M |
| FY2021 | $-408.3M | $512.6M |
| FY2020 | $-608.5M | $359.2M |
| FY2019 | $-181.2M | $-41.5M |
| FY2018 | · | $190.4M |
| FY2017 | · | $40.4M |
| FY2016 | · | $80.4M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$2,061,317,000 | ARGX |
| FY2024 | +$207,669,000 | ARGX |
| FY2023 | −$774,528,000 | QGEN |
| FY2022 | −$1,740,798,000 | QGEN |
| FY2021 | −$1,754,380,000 | QGEN |
| FY2020 | −$1,829,103,000 | QGEN |
| FY2019 | −$1,447,962,000 | QGEN |
The higher-revenue side has changed between ARGX and QGEN over this period. The gap has widened since the earliest year compared.
7 of 18 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +10.8 pp | ARGX |
| FY2024 | +33.9 pp | ARGX |
| FY2023 | −42.1 pp | QGEN |
| FY2022 | −196.8 pp | QGEN |
| FY2021 | −104.9 pp | QGEN |
| FY2019 | −228.2 pp | QGEN |
| FY2018 | −322.9 pp | QGEN |
| FY2017 | −79.9 pp | QGEN |
| FY2016 | −151.3 pp | QGEN |
| FY2015 | −233.5 pp | QGEN |
The higher net margin has changed hands between ARGX and QGEN over this period.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ARGX's net margin has been more volatile than QGEN's over the 10 comparable fiscal years — 111.0 percentage points of standard deviation against 8.2.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ARGX and QGEN over these 10 fiscal years — ARGX led in 2 and QGEN in 8.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ARGX's return on equity has been more volatile than QGEN's over the 11 comparable fiscal years — 20.5 percentage points of standard deviation against 5.7.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ARGX and QGEN over these 11 fiscal years — ARGX led in 2 and QGEN in 9.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.